Syncom Formulations (India) Share Price Prediction 2027: Scenario Targets, Valuation and Technical Outlook

Syncom Formulations (India) share price prediction 2027 comes down to earnings growth and the multiple investors pay for it, and the reported numbers give a measured answer. The stock trades at Rs 23.23 on NSE as of 9 October 2026, 15.5% below its 52-week high of Rs 27.49, after the company reported net profit of Rs 76.44 crore for FY26.

This Syncom Formulations (India) stock forecast 2027 builds conservative, base and bull scenarios from exchange-reported financials, shareholding data and daily price indicators, with every assumption shown.

Click Here – Get Free Investment Predictions

Syncom Formulations (India) Share Price Today and Key Data

The Syncom Formulations (India) share price today is Rs 23.23 on NSE, down 1.44% on the day. The market capitalisation stands at Rs 2,217 crore. Over the past year the price has risen 37.0% from Rs 16.96. Every Syncom Formulations (India) stock forecast figure below starts from this price.

Metric	Value
Company	Syncom Formulations (India) (SYNCOMF)
Current Price	Rs 23.23
52-Week High	Rs 27.49 (30 September 2026)
52-Week Low	Rs 10.21 (30 March 2026)
Market Cap	Rs 2,217 crore
PE Ratio	25.91
Industry PE	37.59
PB Ratio	5.34
EPS (TTM)	Rs 0.91
Return on Equity	18.42%
Debt to Equity	0.00
Dividend Yield	0.42%
Book Value per Share	Rs 4.41

What Is the Syncom Formulations (India) Share Price Prediction for 2027?

The Syncom Formulations (India) share price prediction for 2027 is a conservative case of Rs 26.7, a base case of Rs 27.9 and a bull case of Rs 33.4. Against Rs 23.23, these imply 14.9% upside, 20.1% upside and 43.8% upside. They are model scenarios built from reported EPS growth, not broker targets.

Scenario	EPS Growth Basis	EPS Estimate	PE Multiple	Implied Value	Upside vs Current Price
Conservative Case	Lower of FY26 growth (52.8%) and 4-year CAGR (35.5%) (capped at 15%)	Rs 1.05 (+15.0%)	Unchanged from today (price to EPS ratio kept constant)	Rs 26.7	+14.9%
Base Case	Average of the two (capped at 20%)	Rs 1.09 (+20.0%)	Unchanged from today (price to EPS ratio kept constant)	Rs 27.9	+20.1%
Bull Case	Higher of the two (capped at 25%)	Rs 1.14 (+25.0%)	Re-rated 15.0% toward industry PE of 37.59 (still at or below it)	Rs 33.4	+43.8%

Each target takes today's price of Rs 23.23 and scales it by the EPS growth assumed for that case, which is the same as holding the PE multiple constant. The conservative case uses the lower of the FY26 EPS growth and the 4-year EPS CAGR, the base case uses their average and the bull case uses the higher figure. The bull case also re-rates the PE multiple toward the industry level, because the stock trades below it. Together they form the Syncom Formulations (India) target price range for the FY27 outlook over the next 12 months, and the range is not a point estimate.

Syncom Formulations (India) Share Price Forecast: What Has to Go Right by 2027

Each Syncom Formulations (India) target price below depends on a specific EPS outcome, and the text states that outcome next to the number.

Conservative Case for the Syncom Formulations (India) Share Price Target: Rs 26.7

Reaching Rs 26.7 needs EPS to rise 15.0% to Rs 1.05 while the stock keeps its current PE multiple. That follows the slower 4-year EPS CAGR of 35.5%.

Base Case for the Syncom Formulations (India) Share Price Target: Rs 27.9

Reaching Rs 27.9 needs EPS to rise 20.0% to Rs 1.09, the average of the FY26 growth rate and the 4-year CAGR. Net profit growth of 57.8% in Q1 FY27 is at or above that pace, which supports the target.

Bull Case for the Syncom Formulations (India) Share Price Target: Rs 33.4

Reaching Rs 33.4 needs EPS to rise 25.0% to Rs 1.14 and the PE multiple to re-rate 15.0% toward the industry PE. That is above the 52-week high of Rs 27.49, so it would need a fresh breakout. A daily close above the nearest resistance level of Rs 27.49 (52-week high) would be the first technical confirmation.

Syncom Formulations (India) Financial Performance: Revenue, Profit and Margins

Syncom Formulations (India) earned net profit of Rs 76.44 crore on revenue of Rs 520.51 crore in FY26, with profit up 54.6% and revenue up 7.9% compared with FY25. Diluted EPS was Rs 0.81 against Rs 0.53 a year earlier, and that earnings base anchors the Syncom Formulations (India) share price forecast.

Year	Revenue (Rs Cr)	Net Profit (Rs Cr)	EPS (Rs)	Operating Margin	Net Margin
FY22	231.66	19.79	0.24	14.59%	8.54%
FY23	238.85	20.07	0.24	15.39%	8.40%
FY24	276.91	25.31	0.34	16.48%	9.14%
FY25	482.45	49.43	0.53	15.43%	10.25%
FY26	520.51	76.44	0.81	22.24%	14.69%

In the latest reported quarter, Q1 FY27 (quarter ended June 2026), revenue was Rs 133.36 crore against Rs 122.93 crore a year earlier (+8.5%), and the bottom line was a net profit of Rs 24.85 crore against a net profit of Rs 15.75 crore (+57.8%). Operating margin was 27.12% versus 18.72% in the year-ago quarter. Cash flow from operations was Rs 58.08 crore in FY26 against Rs 23.44 crore in FY25. Together these figures set the earnings base for the Syncom Formulations (India) share price prediction.

Check the Univest Screener for live Syncom Formulations (India) fundamentals

Is Syncom Formulations (India) Overvalued or Undervalued Right Now?

Syncom Formulations (India) trades at a PE of 25.91 against an industry PE of 37.59, which places the stock at a 31.1% discount to the industry average. The price-to-book ratio is 5.34 on a book value of Rs 4.41 per share. Return on equity of 18.42% means the company earns Rs 18.42 of profit for every Rs 100 of shareholder equity.

Debt to equity is 0.00, so borrowings equal about 0% of shareholder equity. The company declared a dividend of Rs 0.10 per share for FY26, a yield of 0.42% at the current price. This valuation context frames the Syncom Formulations (India) stock price prediction for 2027 without relying on any outside forecast.

Syncom Formulations (India) Stock Analysis: Technical Outlook

Syncom Formulations (India) stock trades above its 50-day SMA of Rs 18.57 and above its 200-day EMA of Rs 16.30, and the combined daily indicators read bullish. The 52-week high of Rs 27.49 was set on 30 September 2026, while the 52-week low of Rs 10.21 came on 30 March 2026.

Indicator	Reading	Signal
RSI (14)	61.21	Positive momentum
MACD (12,26,9)	1.54 vs signal 1.51	Bullish
ADX (14)	32.67	Established trend
Supertrend (10,3)	Price above Rs 20.60	Bullish
50-day SMA	Rs 18.57	Price above
200-day EMA	Rs 16.30	Price above

The nearest support level sits at Rs 20.60 (Supertrend) and Rs 18.57 (50-day SMA). The nearest resistance level sits at Rs 27.49 (52-week high). A sustained move above the nearest resistance would support the Syncom Formulations (India) share price prediction 2027 base case, and this Syncom Formulations (India) stock analysis uses daily candles only. Chart signals add context to the Syncom Formulations (India) share price target without changing the earnings maths.

Syncom Formulations (India) Shareholding Pattern

Promoters hold 50.57% of Syncom Formulations (India) as of Jun 2026, unchanged across the last 5 quarters. FII holding is 0.35% (down from 0.41% in Jun 2025) and DII holding is 0.00% (unchanged), which puts combined institutional holding at 0.35%. Public shareholders own 49.08%. Shareholding data is one input for any Syncom Formulations (India) stock forecast.

Key Risks to the Syncom Formulations (India) Share Price Target for 2027

Earnings and Margin Risk

Operating margin has ranged from 14.59% to 22.24% between FY22 and FY26, so a slip toward the lower end would trim the EPS estimate behind the Syncom Formulations (India) stock forecast. Revenue was up 7.9% in FY26, and slower revenue growth would weigh on the profit path.

Size and Liquidity Risk

Market capitalisation stands at Rs 2,217 crore. Investors should check daily traded volumes and order book depth on NSE before sizing a position, because price moves can be sharper when volumes thin out. Liquidity is a practical constraint on any Syncom Formulations (India) stock price target.

Balance Sheet Risk

Debt to equity of 0.00 means borrowings stand at about 0% of shareholder equity. A rise in borrowing costs or a jump in debt would weigh on profit and on the multiple behind the Syncom Formulations (India) share price forecast.

Conclusion

This Syncom Formulations (India) stock analysis puts the share price target range for 2027 at Rs 26.7 to Rs 33.4, with a base case of Rs 27.9 against Rs 23.23 today. The inputs are a PE of 25.91 that sits at a 31.1% discount to the industry average, EPS growth of 52.8% in FY26 and a daily technical setup that reads bullish. The next quarterly result will show which scenario is gaining ground. This analysis is educational, so consult a SEBI-registered advisor before acting on it.

Download the Univest iOS App or Univest Android App to track Syncom Formulations (India) live price and get daily stock recommendations.

Frequently Asked Questions on Syncom Formulations (India) Share Price Prediction 2027

What is the Syncom Formulations (India) share price target for 2027?

Ans. The Syncom Formulations (India) share price forecast for 2027 has a conservative case of Rs 26.7, a base case of Rs 27.9 and a bull case of Rs 33.4. These are model scenarios based on reported EPS growth, and they are not guaranteed outcomes.

What is the Syncom Formulations (India) share price today?

Ans. Syncom Formulations (India) trades at Rs 23.23 on NSE as of 9 October 2026, down 1.44% on the day. The 52-week range is Rs 10.21 to Rs 27.49.

Is Syncom Formulations (India) a good stock to buy for 2027?

Ans. The data points in different directions: the PE of 25.91 is at a 31.1% discount to the industry average, EPS grew 52.8% in FY26 and the daily technical setup reads bullish. This article does not constitute investment advice, so consult a SEBI-registered advisor before deciding.

Can Syncom Formulations (India) stock reach Rs 33.4 in 2027?

Ans. Reaching Rs 33.4 needs EPS to rise 25.0% from Rs 0.91 and the PE multiple to re-rate toward the industry PE of 37.59, plus a daily close above Rs 27.49 (52-week high). This is a scenario, not a guarantee.

What are the support and resistance levels for Syncom Formulations (India)?

Ans. The nearest support levels are Rs 20.60 (Supertrend) and Rs 18.57 (50-day SMA), and the nearest resistance levels are Rs 27.49 (52-week high).

What are the main risks for Syncom Formulations (India) stock in 2027?

Ans. The main risks to the Syncom Formulations (India) share price forecast are a fall in operating margin from the 14.59% to 22.24% range seen since FY22, slower revenue growth after FY26 revenue was up 7.9%, and thin trading volumes. Debt to equity of 0.00 adds balance sheet sensitivity.

How is the Syncom Formulations (India) target price for 2027 calculated?

Ans. Each target scales the current price by assumed EPS growth at a constant PE multiple. The conservative case uses 15.0% growth, the base case 20.0% and the bull case 25.0%, all drawn from the company's reported FY26 and 4-year EPS growth.